ライフサイエンスコーパス: antibody production

1 f the most critical steps in hapten-specific antibody production.

2 protein that suppresses B-cell function and antibody production.

3 ulates some aspects of B-cell activation and antibody production.

4 a suitable format for therapeutic monoclonal antibody production.

5 leads to switch of the cellular response to antibody production.

6 , IL-5 and IL-13 and diminished OVA-specific antibody production.

7 aive B cells and how this relates to de novo antibody production.

8 signaling, cell survival, proliferation, and antibody production.

9 ysis, flow cytometry, suppression assay, and antibody production.

10 at least in part) for the observed defect in antibody production.

11 d organ development, B cell development, and antibody production.

12 cells are critical for PF4/heparin-specific antibody production.

13 nteractor (TACI) often display dysfunctional antibody production.

14 cells require help from T cells to initiate antibody production.

15 ge of distinct immune deficiencies affecting antibody production.

16 ly prevented donor-specific immunoglobulin M antibody production.

17 with significant implications in industrial antibody production.

18 ression of cellular host responsiveness, and antibody production.

19 of T-cell proliferation and T-cell-dependent antibody production.

20 l differentiation, resulting in dysregulated antibody production.

21 play critical roles in the regulation of IgE antibody production.

22 lymph nodes, with plasma cell formation and antibody production.

23 ma cell maturation, and negligible antiviral antibody production.

24 at a CD4 level but is broken at the level of antibody production.

25 and consequent germinal center formation and antibody production.

26 ic immunity and NP-immune protection require antibody production.

27 icular B-cell migration and T-cell-dependent antibody production.

28 wide application in vaccine development and antibody production.

29 m immunoglobulin G, A, and/or M with loss of antibody production.

30 ntrol the GC reaction, along with pathogenic antibody production.

31 ect in the formation of germinal centers and antibody production.

32 days as indicated by a complete block of IgG antibody production.

33 l as the result of SV40 Tag immunization and antibody production.

34 tigen-specific whole immunoglobulin and thus antibody production.

35 colonize the bone marrow and do not sustain antibody production.

36 ts as early as 18 days, suggesting antidonor antibody production.

37 respond to LCMV infection and support IgG2a antibody production.

38 otes B cell growth, survival and memory, and antibody production.

39 activation, cytolytic effector function, and antibody production.

40 tokines (IL-17, TNFalpha, and IFNgamma), and antibody production.

41 ng plasma cells (PCs) is vital for sustained antibody production.

42 work together to influence anti-factor VIII antibody production.

43 on spirochete clearance or Borrelia-specific antibody production.

44 ory and relatively short-lived, low-affinity antibody production.

45 l responses as well as robust and protracted antibody production.

46 regions of PilE alone are not sufficient for antibody production.

47 CSR) before being selected for high-affinity antibody production.

48 differentiate into plasma cells committed to antibody production.

49 also reduced cardiac myosin-specific DTH and antibody production.

50 pendent and depression of Th1 cell-dependent antibody production.

51 ICA) antigens are polymorphic and can elicit antibody production.

52 3 content and impairs B cell development and antibody production.

53 , antigen presentation, and T cell-dependent antibody production.

54 roliferation, germinal center formation, and antibody production.

55 ent antigen-induced B cell proliferation and antibody production.

56 one marrow (BM) and contributes to long-term antibody production.

57 ion by CII-specific T cells and CII-specific antibody production.

58 sadvantage to PCs for long-term survival and antibody production.

59 lasma cells is required to sustain long-term antibody production.

60 cytic capacity was further enhanced after TI antibody production.

61 cialized in supporting B-cell maturation and antibody production.

62 for modulating the function of TFR cells and antibody production.

63 T-cell responses, as well as B-cell-mediated antibody production.

64 le antigen-specific mouse memory B cells for antibody production.

65 d inhibit Tfh-mediated B-cell activation and antibody production.

66 of bone marrow long-lived plasma cell (LLPC) antibody production.

67 o and to move into target tissues to support antibody production.

68 GC B cells, and high-affinity class-switched antibody production.

69 plasma cell generation and antigen-specific antibody production.

70 roduce energy and building blocks supporting antibody production.

71 entiate into plasma cells thereby leading to antibody production.

72 lling and increased B-cell proliferation and antibody production.

73 tions that could transform the technology of antibody production.

74 ased T-cell activation, thymic selection, or antibody production.

75 follicular helper T cell (TFH cell)-mediated antibody production.

76 ted with a severe impairment in SIV-specific antibody production.

77 hat the BiP cofactor Sil1 is dispensable for antibody production.

78 ly represses plasma cell differentiation and antibody production.

79 cessed antigen, was not sufficient to induce antibody production.

80 V reflected the specificity of high-affinity antibody production.

81 to diminished germinal center formation and antibody production.

82 ctivity, cell surface marker expression, and antibody production.

83 important role in many stages of therapeutic antibody production.

84 Tertiary lymphoid tissue formation and local antibody production add to intrarenal complement activat

85 t heart transplant recipients, normal anti-A antibody production after "A-into-O" piglet kidney trans

86 host lymphocytes and better T-cell-dependent antibody production after 1 Gy compared with 2 Gy TBI.

87 ory T- and B cells as well as virus-specific antibody production after acute infection.

88 thin the CNS that facilitate continued local antibody production after infection.

89 were independently associated with decreased antibody production after influenza vaccination in healt

90 oiler sires were found to be associated with antibody production after S. enterica serovar Enteritidi

91 Durable antibody production after vaccination or infection is me

92 vation and has been shown to be required for antibody production after vaccination with attenuated Sa

93 erse events, serum arginine, AFP levels, and antibody production against ADI were measured on a regul

94 sing the NiNLP platform resulted in elevated antibody production against His-tagged influenza hemaggl

95 -versus-host disease (GVHD), as evidenced by antibody production against sex-mismatched, Y chromosome

96 invasive S. pyogenes infection respond with antibody production against sHIP suggest a role for the

97 x and is known to include virus-neutralizing antibody production against surface glycoproteins encode

98 Such an event spurs antibody production against these immunoconjugates, poss

99 Antibody production against TT peaked approximately 2 we

100 activation of plasma cells with significant antibody production already in ETR, followed by a cresce

101 es evidence of iNK T cell help for antilipid antibody production, an important aspect of infections,

102 tion, vaccination, and trauma with increased antibody production and a more T helper (Th)2-predominan

103 abling efficient knobs-into-holes bispecific antibody production and a robust path to generating high

104 Antibody production and affinity maturation are driven b

105 at genes related to immune functions such as antibody production and antigen processing were increasi

106 onsible primarily for the basic functions of antibody production and cell-mediated immune responses,

107 tion in vitro and plays an important role in antibody production and class switching in vivo.

108 ecruitment and IL-17-dependent regulation of antibody production and crystal deposition.

109 tance of CD4 T-cell help in the induction of antibody production and cytotoxic-T-lymphocyte responses

110 Intraocular antibody production and DNA was absent in all tested pat

111 Freund's adjuvant (IFA), resulted in higher antibody production and earlier remyelination in SFV-inf

112 control of overexuberant B-cell activation, antibody production and generation of memory.

113 eficient mice exhibited moderately increased antibody production and germinal center responses when c

114 ey disease manifestations including anti-DNA antibody production and glomerulonephritis.

115 chanisms by which the PD-1 pathway regulates antibody production and help reconcile inconsistencies s

116 eptor FcgammaRIIb is a negative regulator of antibody production and inflammatory responses.

117 How TACI promotes antibody production and inhibits lymphoproliferation is

118 s of rat ECDI-SPs effectively prevented such antibody production and led to the indefinite survival o

119 ns in FCGR2B, which controls factors such as antibody production and macrophage activation, are impor

120 The suppression of B cell antibody production and metabolism by TFR cells was dura

121 imize T lymphocyte reactions and to maximize antibody production and passive immunization protocols a

122 Malaria-induced antibody production and pathology were unaltered by 11be

123 that this localization normally facilitates antibody production and plays a role in B cell abnormali

124 studies for ligand screening, drug delivery, antibody production and protein complex formation.

125 e developed Chlamydia-specific IFN-gamma and antibody production and resolved the infection within 30

126 ovides a new target and strategy to modulate antibody production and responses with profound therapeu

127 4 and anti-alphabeta TCR abrogated antidonor antibody production and resulted in prolonged skin graft

128 ey cell population responsible for long-term antibody production and serological memory.

129 ole of long-lived plasma cells in persistent antibody production and the factors regulating their lon

130 Antibody production and the frequency of antibody-secret

131 shape the Type-2 immune response by guiding antibody production and the memory response.

132 Monitoring antidonor antibody production and the use of new therapies includi

133 lymphoid and peripheral tissues, and control antibody production and tissue repair.

134 in allergic immune responses, including IgE antibody production and type 2 cytokine-mediated inflamm

135 al burden for autoimmune disease or abnormal antibody production and were not enriched in the genetic

136 ction leads to enhanced local virus-specific antibody production and, thus, increased protection agai

137 f tolerance can lead to PF4/heparin-specific antibody production, and B-cell tolerance may play an im

138 m B6.TC mice increased B cell proliferation, antibody production, and chemokine receptor expression a

139 te activities, adhesion molecule expression, antibody production, and cytokine and inflammatory media

140 We measured the proliferation, antibody production, and expression of activation marker

141 mice displayed defective B cell maturation, antibody production, and formation of secondary lymphoid

142 tive influenza virus enhances virus-specific antibody production, and importantly, this effect is dep

143 lationships between intermediary metabolism, antibody production, and lifespan.

144 populations, and decreases in proliferation, antibody production, and migration to chemokines.

145 globulin raised the platelet counts, reduced antibody production, and normalized the thymic and splen

146 VII collagen-immunized mice, suppressed auto-antibody production, and reduced dermal neutrophilic inf

147 s to germinal center (GC) B cells to support antibody production, and suppressive T-follicular regula

148 cytes, their regulatory roles independent of antibody production, and the molecular events that make

149 but the mechanisms by which CTLA-4 regulates antibody production are not known.

150 nor T-cell responses that support pathogenic antibody production are required for cGVHD development.

151 of SAP, several routes of NKT cell-mediated antibody production are still accessible.

152 ysical properties of complexes that initiate antibody production are unknown.

153 However, in contrast to deficient anti-A antibody production as seen long-term after "A-into-O" i

154 ulations during infection or decreased serum antibody production, as IL-6 KO mice had similar composi

155 ific delayed-type hypersensitivity (DTH) and antibody production at 21 days postinfection.

156 er) that now allow for effective recombinant antibody production at a reasonable cost.

157 d myeloid signals to orchestrate innate-like antibody production at the interface between the immune

158 gosity has no effect on organ development or antibody production but prolongs the latency period and

159 NKT cells in SAP(-/-).BALB/c mice adjuvated antibody production, but not the germinal center reactio

160 minant theory implicates antigen-independent antibody production by a subset of long-lived plasma cel

161 MP2A acts directly on the B cell to increase antibody production by augmenting the expansion and surv

162 functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patient

163 Although neutralizing antibody production by B cells and cytotoxic activity of

164 t CpG promotes pro-inflammatory cytokine and antibody production by B cells via the Toll-like recepto

165 impair T cell expansion and durable-specific antibody production by B cells.

166 nt of adaptive immune responses as they help antibody production by B cells.

167 tory pathways that enable continuous natural antibody production by B-1 cells, the main cellular sour

168 The duration of antibody production by long-lived plasma cells varies wi

169 dy responses that are characterized by rapid antibody production by marginal zone and B1 B cells.

170 ssed in vitro immunoglobulin G (IgG) and IgA antibody production by memory B cells.

171 LRBA-deficient TFH cells supported in vitro antibody production by naive LRBA-sufficient B cells.

172 To specifically target antibody production by plasma cells and determine the im

173 Thus, IL-6 promotes antibody production by promoting the B cell helper capab

174 e able to inhibit lipopolysaccharide-induced antibody production by splenocytes in vitro, and kynuren

175 processes it enables, whether the process is antibody production by the immune system or tissue diffe

176 anisms is limited to thymus-independent (TI) antibody production by the marginal zone (MZ) B cells, l

177 With technical advances in human antibody production, clues about how antibodies recogniz

178 Antibody production correlated with prior reports of tar

179 Increased antibody production correlated with robust germinal cent

180 del, potential effects of IL-17 cytokines on antibody production could be distinguished from critical

181 gulate several aspects of immunity including antibody production, cytokine secretion, and T-cell acti

182 ocytes derived from B-cell-deficient mice or antibody production-deficient mice were unable to effici

183 telomeric ODN suppress B-cell activation and antibody production demonstrating a natural mechanism fo

184 on is impaired by HIV infection, and loss of antibody production depends on CD4(+) T cell depletion.

185 V(H) replacement, we generated mice in which antibody production depends on the replacement of a nonp

186 er finding demonstrates that anti-glycolipid antibody production does not require cognate help from V

187 nal center (GC) B cells and antigen-specific antibody production during acute infection with lymphocy

188 mechanisms that drive B cell activation and antibody production during chronic airway inflammation.

189 Antiviral antibody production during respiratory syncytial virus (

190 plasma cell development and antigen-specific antibody production during T cell-dependent immune respo

191 e of a new mechanism by which IL-6 regulates antibody production during viral infection, and a novel

192 promise in cell surface marker expression or antibody production either in naive mice or in the conte

193 VIII-deficient mouse model demonstrated that antibody production from FVIII-primed spleen cells in vi

194 ntigen, because there were no differences in antibody production from recipients matched or mismatche

195 Antibody production from tissue was measured using Lumin

196 lted in lower bacteremia, increased specific antibody production, higher production of CXCL13 and IL-

197 te development but impaired T cell-dependent antibody production, IgG antibody affinity maturation, a

198 cells in the periphery and T-cell-dependent antibody production improved in aged mice.

199 gnificantly reduced B-cell proliferation and antibody production in allogeneic culture (P<0.01 vs. co

200 cherichia coli and could thus make secondary antibody production in animals obsolete.

201 None of the patients had local antibody production in either ocular or cerebrospinal fl

202 of B cells to plasma cells and high affinity antibody production in germinal centers (GCs), and Tfh d

203 ere immune reaction with more than 100 times antibody production in group II compared with group I.

204 FVIII plasmid therapy did not induce antibody production in HemA/Foxp3-Tg mice.

205 ocated to the cell surface, where it elicits antibody production in infected chickens.

206 nesis of allergies, and on the mechanisms of antibody production in memory B cell responses.IgE is an

207 tidis induces significant serum bactericidal antibody production in mice and is a candidate meningoco

208 Lack of CD244 is associated with auto-antibody production in mice, and lower expression of hum

209 oosts antigen-specific T cell activation and antibody production in mice.

210 that incites such prevalent anti-PF4/heparin antibody production in more than 50% of patients exposed

211 o PF4/heparin-specific B-cell activation and antibody production in patients developing HIT.

212 to major isotypes) in activated B cells and antibody production in plasma cells.

213 acquisition of adaptive immune responses and antibody production in response to foreign antigens.

214 ere that B cell proliferation and polyclonal antibody production in response to Gram-negative bacteri

215 by low serum immunoglobulin (Ig) M, low IgM antibody production in response to S pneumoniae followin

216 eic acids stimulates interferon and anti-DNA antibody production in SLE.

217 SP90b1 ablation in B cells was an attenuated antibody production in the context of TLR stimulation.

218 ther molecular chaperone system was used for antibody production in the LPS-stimulated splenic B cell

219 ted MV with NDV led to increased MV-specific antibody production in the presence and absence of passi

220 cells is required for IL-6 to promote B cell antibody production in vitro.

221 s, the role of TLRs in B-cell activation and antibody production in vivo is not yet known.

222 and potentiates steady-state and postimmune antibody production in vivo.

223 at activate TLR2 and TLR4 restored long-term antibody production in ZBTB20-deficient chimeras through

224 y repressing plasma cell differentiation and antibody production, in addition to its opposing, active

225 effects of IL-14 on B cell proliferation and antibody production, increases in IL-14 transcript level

226 tion, histological lesions, and neutralizing antibody production, indicating that this monkey model i

227 eficient mice, suggesting that pDC-dependent antibody production influences viral clearance.

228 actors but enhanced immunity with respect to antibody production, innate cytokines, and chemokines.

229 ti-myelin-oligodendrocyte glycoprotein (MOG) antibody production, interleukin (IL)-4, IL-8, IL-10, IL

230 Antibody production is a key feature of the vertebrate i

231 Although antibody production is a major immune defense mechanism

232 Antibody production is a metabolically demanding process

233 Most antibody production is based on using single antigens, h

234 bviral particles is high but either anti-HBV antibody production is fast, the antibody affinity is hi

235 HCV-specific antibody production is impaired by HIV infection, and lo

236 We further demonstrate antinuclear antibody production is influenced by the presence of com

237 However, the B-cell origin of HIT antibody production is not known.

238 cells and their participation in SIV-induced antibody production is not well understood.

239 allenge with PF4/heparin complexes, and that antibody production is severely impaired in B-cell-speci

240 B cell antibody production is thought to be crucial for protect

241 idered to be T-cell independent, whereas IgE antibody production is thought to involve sequential cla

242 nce of B lymphocytes to present antigens for antibody production is well documented.

243 ersus Th2 immune responses and increases MOG antibody production, leading to exacerbation of demyelin

244 he time and costs associated with monoclonal antibody production limit the potential for portable dia

245 at the therapeutic intervention that reduces antibody production may prolong graft survival in transp

246 By examining the pathways to antibody production mechanistically, we hope to identify

247 xpected to elicit cognate iNKT cell help for antibody production, namely those that can stimulate iNK

248 Spontaneous antibody production of different isotypes as well as the

249 After activation of cells with anti-CD3/CD28 antibody, production of the TH1-type cytokine IFNgamma,

250 SV challenge was independent of neutralizing antibody production or cell-mediated adaptive immunity.

251 l-intrinsic TLR signals are not required for antibody production or maintenance.

252 transplantation; however, therapy to control antibody production or to alter its impact on the allogr

253 inherited deficits in immune function (e.g., antibody production or type I IFN signaling), as well as

254 4; 90% vs 69% with or without tumor-specific antibody production; P = .027).

255 operties that hinder the HPA high-throughput antibody production pipeline.

256 tigen and is the basis for a next-generation antibody production platform.

257 with epitopes identified that correlate with antibody production, proliferative T-cell responses, or

258 ing profiles eliciting >10-fold increases in antibody production relative to bolus vaccination post p

259 over time, leading to a progressive loss of antibody production relative to wild-type controls.

260 for over 2 months, and elicited anti-non-Gal antibody production remained suppressed for the duration

261 n a cell-contact-independent manner, reduced antibody production, retarded the development of nephrit

262 xamethasone increased B-cell populations and antibody production, signifying an increased humoral imm

263 -Ia, they might be useful in suppressing HLA antibody production, similar to the way anti-RhD Abs sup

264 hich ALPS results in anti-polysaccharide IgM antibody production-specific defect.

265 Here we present a bispecific-antibody production strategy that relies on co-culture o

266 se appears to be independent of cytokine and antibody production, suggesting modulation of antigen pr

267 s is followed by T and B cell proliferation, antibody production, T cell differentiation, and cytokin

268 High-affinity-antibody production, T-cell activation, and interferon u

269 In the area of antibody production, technologies based on the modificat

270 Despite the significant effect on antibody production, tetanus toxoid and measles IgG leve

271 rodentium induces systemic T-cell-dependent antibody production that facilitates clearance of the ba

272 s L. major, or a type 2 response, leading to antibody production that is ineffective against intracel

273 CD4 T cells are needed for B cell-driven antibody production that leads to immune complex formati

274 a novel platform to inhibit antigen-specific antibody production that preserves the immune system's a

275 High-affinity antibody production through the germinal centre (GC) res

276 l, and eosinophil activation, as well as IgE antibody production, thus protecting against helminthes

277 ault secretion pathway and further increased antibody production to 36.4 microg/g root dry weight per

278 memory with seasonal influenza to facilitate antibody production to H7 HA.

279 Aberrant antibody production to otherwise harmless antigens may r

280 enerates sufficient antigen-specific humoral antibody production to protect from mucosal viral challe

281 itch, our study places IRF4 in the center of antibody production toward T-cell-dependent antigens.

282 C reactions that drive B cell maturation and antibody production, ultimately determining B cell fate.

283 yperresponsive in terms of proliferation and antibody production upon BCR stimulation; however, B cel

284 elopment, and cellular mechanisms leading to antibody production versus immune tolerance to FVIII, ar

285 inct states, guiding immune responses toward antibody production via Tfh cells or inflammation by Tef

286 When local anti-CTLA-4 antibody production was combined with Treg inhibition, p

287 The decrease in antibody production was consistent with the efficacy of

288 Local antibody production was determined by Goldmann-Witmer co

289 Seroconversion and neutralizing antibody production was significantly delayed in animals

290 es and genetic polymorphisms predisposing to antibody production we serially monitored 24-hour protei

291 -/-)), and to distinguish this function from antibody production, we created transgenic (Tg) mice tha

292 Differences in anti-HLA antibody production were detected in only 3/212(1.4%) pa

293 B-cell proliferation, differentiation and antibody production were determined.

294 Follicular Tregs (Tfr cells) inhibit antibody production, whereas follicular Th cells (Tfh ce

295 ine inhibits T cell proliferation and alters antibody production, which are important components of a

296 hat ischemic renal injury leads to a rise in antibody production, which may be harmful to renal allog

297 might combine IL-21-mediated T-cell aid for antibody production while maintaining TH1 cytokine expre

298 esponse of B cells in vitro but also trigger antibody production with class switch recombination in v

299 iated with IgE, IgG, and IgG(4) anti-Bla g 5 antibody production, with a significant correlation betw

300 quely poised to promote B-cell responses and antibody production within pathologically inflamed non-l